Loading patent…
AssigneeArrowhead Pharmaceuticals, Inc.
InventorsZhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
Estimating the term…
Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.
A method of making an RNAi agent for inhibiting expression of a Hepatitis B Virus gene, comprising annealing together an antisense strand and a sense strand, wherein:
A method of treating a subject having a disease, disorder, or condition associated with a Hepatitis B virus infection in the subject, comprising administering to the subject:
Dependencies are inferred from the claim text.